Pacira Pharmaceuticals Stock
Price
Target price
€21.20
€21.20
-1.850%
-0.4
-1.850%
€30.00
06.08.26 / Stuttgart Stock Exchange
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pacira Pharmaceuticals Stock
A loss of -1.850% shows a downward development for Pacira Pharmaceuticals.
Our community is currently high on Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 30 € shows a positive potential of 41.51% compared to the current price of 21.2 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -1.850% | -7.018% | -5.357% | 6.000% | -1.852% | -38.728% | -58.431% |
| Collegium Pharmaceutical Inc | 0.000% | 0.654% | -1.911% | 4.762% | -25.604% | 42.593% | 79.070% |
| Corcept Therapeutics Inc. | 0.980% | -3.486% | 17.777% | 54.317% | 40.099% | 242.143% | 426.374% |
| Savara Inc. | 0.000% | 0.021% | -14.178% | 106.504% | -11.943% | 38.899% | 344.476% |
Comments
Pacira BioSciences (PCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (PCRX) had its price target raised by Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat